LILRB1 and melanoma: Hence, LILRB1 may be an ideal target for tumor therapy.369 Preclinical data show that BND-22 exerts broad antitumor effects by targeting LILRB1-mediated “don’t eat me” signals in macrophages and activating NK and CD8+ lymphocytes, effectively inhibiting tumor growth in melanoma and colorectal cancer, prolonging the survival of model mice, and inhibiting the spread of cancer cells.